How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

AML Blood Test

Organization name

PROvendis GmbH

Profile

Invention

Diagnosing leukemia, especially acute myeloid leukemia (AML), is hindered due to the unspecific symptoms of the disease. Unfortunately misdiagnoses and mistreatments with antiviral or antibiotic medicine lead to a loss of precious time in fighting against this type of cancer. Scientists from the University of Bonn tackled this challenge by developing a blood test. This test is based on one of the most advanced approaches of gene expression profiling: gene signatures. By adaptive learning and simulation the new blood test for acute myeloid leukemia (AML-BT) was generated. With an “RNA-fingerprint”, the analysis of the different indicator RNAs - showing a decreased or increased expression rate as indication for AML - can be conducted and used for a reliable diagnosis.

Commercial Opportunities

The present invention provides an easy accessible prognosis or detection of AML, notably the early detection of AML, as well as a kit and a (micro) array suitable for the mentioned method.On behalf of the University of Bonn, PROvendis offers access to rights for commercial use as well as the opportunity for further co-development.

Current Status

In case of interest we are pleased to inform you about the current patent status.

Benefits

  • diagnosis of AML at an early stage is possible
  • the analysis of peripheral blood is sufficient for the diagnosis of AML

About PROvendis GmbH

PROvendis offers companies certified and patented innovations from North Rhine-Westphalian universities. The core function of the enterprise is to market patentable and commercially exploitable inventions. PROvendis GmbH was founded in 2001 as a wholly owned subsidiary of Zenit GmbH, a management consultancy firm in cooperation with the state of North Rhine-Westphalia. Since January of 2002, PROvendis has been the service provider for the universities of the state of North Rhine-Westphalia. Within the scope of the BMBF commercialization campaign, the Federal Ministry for Education and Research (BMBF) supports the activities of PROvendis.

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries